Category: Teva Pharmaceutical Industries

Teva Said to Consider Options for Branded Generics Unit

Israeli drugmaker Teva Pharmaceutical Industries Ltd. is weighing options including a sale of its branded generics products business as it works to reduce debt, according to people familiar with the matter. The business could be valued at several billion dollars, and Teva may also consider spinning off the unit, the people said, asking not to be identified because the deliberations are private.

Teva Loses CEO, Leaving Investors to Guess What’s Next

Teva Pharmaceutical Industries Ltd. announced the departure of its chief executive officer after just three years and said it would undertake a thorough review of its business, leaving the world’s largest generic-drug maker without a permanent leader following lowered profit forecasts that sent the share price plunging. CEO Erez Vigodman has stepped down, and Chairman Yitzhak Peterburg will hold the job on an interim basis while a search is conducted for a successor, the Petach Tikva, Israel-based company said in a statement late Monday.

Teva Searches for a New CEO

The Jerusalem-based pharmaceutical company named Dr. Yitzhak Peterburg as interim CEO after Erez Vigodman stepped down following a mutual agreement with the board. Teva Pharmaceutical is looking for a new CEO after Erez Vigodman stepped down following a mutual agreement with the board, the company said Monday.

Teva Plunges After U.S. Judge Invalidates Four Copaxone Patents

Teva Pharmaceutical Industries Ltd. plunged to the lowest in more than a decade following a U.S. court ruling that invalidated four patents on its best-selling multiple sclerosis drug Copaxone. The ruling, issued late on Monday, may open the door to generic competition for a drug that generates a fifth of Teva’s $20 billion in annual sales.

IEFA, EFU: Big ETF Inflows

Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the iShares Core MSCI EAFE ETF , which added 14,000,000 units, or a 4.5% increase week over week. Among the largest underlying components of IEFA, in morning trading today Teva Pharmaceutical Industries is down about 0.2%, and NXP Semiconductors is lower by about 0.2%.

article

After the company reported in December that a key late-stage drug had come up short in trials, a sharp sell-off caused Opko Health to finish the fourth quarter down 12.2%, capping a 7.5% loss for the year,according to S&P Global Market Intelligence . Opko Health is run by billionaire CEO Phillip Frost, and until recently, Frost has been very successful at commercializing clinical-stage drugs that he’s purchased for Opko Health at bargain prices.

Mylan, Teva Led Peers in – Anomalous’ Price Moves, Study Says

About one in 19 generic drugs sold in the U.S. during the past three years have undergone major price hikes that may be consistent with collusion, according to a wide-ranging study that comes in the middle of a sprawling Justice Department investigation into pharmaceutical price-fixing. Fideres Partners LLP, a London-based consultancy that works with law firms to bring litigation against companies, reported “anomalous pricing patterns” in scores of generic drugs sold in the U.S. from 2013 to 2016.